Multiple myeloma can be attacked and destroyed by measles virus. Specificity of this approach can be achieved by arming the virus with a new specificity, making it exclusive toxic to multiple myeloma. Delivery of virus to multiple myeloma cells and protection from neutralizing antibodies is achieved by hiding the measles virus in T-cells. As some T-cells express homing receptors for the bone marrow, up front selection of T-cells with bone marrow homing capabilities would allow delivery of the retargeted virus in close proximity to the multiple myeloma cells. Therefore, this approach potentially represents a new treatment option for multiple myeloma.